EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY

Shanlee M Davis iD, Susan Howell iD, Jennifer Janusz iD, Najiba Lahlou iD, Regina Reynolds, Talia Thompson iD, Karli Swenson iD, Rebecca Wilson iD, Judith L Ross iD, Philip S Zeitler iD, Nicole R Tartaglia iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf217 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Shanlee M Davis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Endocrinology, University of Colorado SOM, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Testosterone, Klinefelter Syndrome, Child Development, Neurodevelopmental Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NCATS NIH HHS, NICHD K23HD092588.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the minipuberty period of infancy.

Objective

We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.

Design

Double-blind randomized controlled trial, 2017-2021.

Setting

US tertiary care pediatric hospital. Patients Infants 30 to 90 days of age with prenatally identified, nonmosaic 47,XXY (n = 71).

Intervention

Testosterone cypionate 25 mg IM injections every 4 weeks for 3 doses. Main outcome measures The a priori primary outcomes were change in percent fat mass z-scores and change in the total composite percentile on Alberta Infant Motor Scales assessment from baseline to 12 weeks.

Results

The between-group difference in change in percent fat mass z-scores was −0.57 (95% CI, −1.1 to −0.06; P = .03), secondary to greater increases in lean mass in the testosterone-treated group (1.5 ± 0.4 kg vs 1.2 ± 0.4; P = .001). Testosterone suppressed gonadotropins and inhibin B (P < .001 for all). In contrast, there were no significant group differences in short-term motor, cognitive, or language outcomes (P > .15 for all).

Conclusions

In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure; however, this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY; however, long-term follow-up on physical health, neurodevelopment, and testicular function is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneKlinefelter SyndromeChild DevelopmentNeurodevelopmental DisordersHumansDouble-Blind MethodMaleInfantFemaleInfant, NewbornBody CompositionFollow-Up Studies

Stichwörter der Autor:innen

Klinefelter syndromecritical windowmini puberty periodtestosterone

Substanzen

Testosterone

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Endocrinology, University of Colorado SOM, Aurora, CO 80045, USA.
  • eXtraOrdinarY Kids Clinic and Research Program, Children's Hospital Colorado, Aurora, CO 80045, USA.
  • Department of Pediatrics, Section of Neurology, University of Colorado SOM, Aurora, CO 80045, USA.
  • Laboratoire BPR Analyses Spécialisées, Département D'Hormonologie Spécialisée, 45700 Pannes, France.
  • Department of Pediatrics, Section of Neonatology, University of Colorado SOM, Aurora, CO 80045, USA.
  • Department of Pediatrics, Section of Developmental Pediatrics, University of Colorado SOM, Aurora, CO 80045, USA.

ORCID-Profile: Shanlee M Davis, Susan Howell, Jennifer Janusz, Najiba Lahlou, Talia Thompson, Karli Swenson, Rebecca Wilson, Judith L Ross, Philip S Zeitler, Nicole R Tartaglia

Förderung

  • NICHD NIH HHS
  • NCATS NIH HHS
  • NICHD K23HD092588
  • NIH/NCATS
  • UM1 TR004399

Zitieren

APA

Davis, S. M., Howell, S., Janusz, J., Lahlou, N., Reynolds, R., Thompson, T., Swenson, K., Wilson, R., Ross, J. L., Zeitler, P. S., & Tartaglia, N. R. (2025). Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf217

Vancouver

Davis SM, Howell S, Janusz J, Lahlou N, Reynolds R, Thompson T, et al. Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf217

BibTeX
@article{Davis2025,
  author = {Davis, Shanlee M and Howell, Susan and Janusz, Jennifer and Lahlou, Najiba and Reynolds, Regina and Thompson, Talia and Swenson, Karli and Wilson, Rebecca and Ross, Judith L and Zeitler, Philip S and Tartaglia, Nicole R},
  title = {Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf217}
}
Kostenlos starten →